Edition:
United States

Bristol-Myers Squibb Co (BMY.N)

BMY.N on New York Stock Exchange

54.39USD
25 May 2017
Change (% chg)

$0.57 (+1.06%)
Prev Close
$53.82
Open
$53.98
Day's High
$54.58
Day's Low
$53.70
Volume
2,715,826
Avg. Vol
2,975,504
52-wk High
$77.10
52-wk Low
$46.01

Latest Key Developments (Source: Significant Developments)

Health Canada approves Bristol-Myers' opdivo(nivolumab)
Wednesday, 17 May 2017 08:00am EDT 

May 17 (Reuters) - Bristol-Myers Squibb Co :Health Canada approves opdivo (nivolumab) for the treatment of squamous cell carcinoma of the head and neck.Bristol- Myers Squibb Co says data to support approval was based on Checkmate-141, a phase three clinical trial.  Full Article

Jana Partners cuts sole share stake in Bristol-Myers Squibb
Monday, 15 May 2017 05:56pm EDT 

May 15 (Reuters) - Jana Partners LLC:Jana Partners cuts sole share stake in Bristol-Myers Squibb Co by 81.5 percent to 716,389 shares - SEC filing.Jana Partners - Change in holdings are as of March 31, 2017 and compared with the previous quarter ended as of Dec 31, 2016.  Full Article

Appaloosa LP dissolves share stake in Bristol Myers, Qualcomm
Friday, 12 May 2017 04:33pm EDT 

May 12 (Reuters) - Appaloosa LP::Appaloosa LP dissolves share stake in Bristol Myers Squibb Co - sec filing.Appaloosa LP dissolves share stake in J C Penney Co Inc.Appaloosa LP dissolves share stake in Qualcomm Inc.Appaloosa LP ups share stake in Micron Technology Inc from 3.25 million shares to 6.7 million shares.Appaloosa LP ups share stake in Southwest Airlines Co from 1.2 million shares to 3.1 million shares.Appaloosa LP - change in holdings are as of March 31, 2017 and compared with the previous quarter ended as of Dec 31, 2016.  Full Article

Bristol-Myers Squibb, Calithera Biosciences expand collaboration
Wednesday, 10 May 2017 06:59am EDT 

May 10 (Reuters) - Bristol-myers Squibb Co :Bristol-Myers Squibb and Calithera Biosciences expand collaboration evaluating opdivo (nivolumab) in combination with CB-839 into non-small cell lung cancer and melanoma.Calithera Biosciences Inc - study to evaluate potential of CB-839 plus opdivo to target immunosuppressive cancer metabolism in tumor microenvironment.  Full Article

China FDA approves country's first all-oral regimen for chronic Hepatitis C
Friday, 28 Apr 2017 07:19am EDT 

April 28 (Reuters) - Bristol-myers Squibb Co :China FDA approves country's first all-oral regimen for chronic Hepatitis C, daklinza (daclatasvir) in combination with sunvepra (asunaprevir).Bristol-Myers Squibb Co - daklinza also approved in China for use in combination with other agents, including sofosbuvir, for HCV genotypes 1-6.Bristol-Myers Squibb Co - sofosbuvir is under review by China food and drug administration and is not currently licensed in China.  Full Article

Bristol-Myers says discontinued development of drug to treat breast and gastric cancer in Q1
Thursday, 27 Apr 2017 11:53am EDT 

April 27 (Reuters) - Bristol-Myers Squibb Co ::Employee workforce reductions were about 900 for quarter-ended March 31, across all regions for manufacturing, selling, research and development personnel - SEC filing.In Q1 2017, discontinued development of FS102 which was in Phase I development for treatment of breast and gastric cancer.Will not exercise its option to purchase F-Star Alpha which was previously consolidated by company as a variable interest entity.IPRD charge of $75 million was included in research and development expense and attributed to noncontrolling interest in Q1.  Full Article

Bristol-Myers CFO: potential for 2017 U.S. growth for Opdivo
Thursday, 27 Apr 2017 11:48am EDT 

April 27 (Reuters) - Bristol-myers Squibb :Cfo says now believes "there is potential for Opdivo to grow in the U.S. this year," even with increased competition.Cfo says continues to expect international sales for opdivo to grow for the full year.  Full Article

Transgene and Bristol-Myers Squibb announce clinical research collaboration
Tuesday, 25 Apr 2017 01:33am EDT 

April 25 (Reuters) - Transgene Sa : :Co and Bristol-Myers Squibb announce clinical research collaboration to evaluate TG4010 with Opdivo and Standard Chemotherapy in First Line Non-Small Cell Lung Cancer.Phase 2 clinical trial will explore potential of combining Transgene's TG4010, in conjunction with Bristol-Myers Squibb's immune checkpoint inhibitor, Opdivo.Under terms of agreement, Transgene will be sponsor of trial. Bristol-Myers Squibb will provide Opdivo for use in study..  Full Article

Bristol-Myers gets positive CHMP opinion recommending approval of Opdivo for treatment of a type of bladder cancer
Friday, 21 Apr 2017 02:06pm EDT 

April 21 (Reuters) - Bristol-Myers Squibb Co : :Bristol-Myers Squibb receives positive CHMP opinion recommending approval of Opdivo (Nivolumab) for the treatment of patients with previously treated locally advanced or metastatic urothelial carcinoma, a type of bladder cancer.CHMP opinion based on tumor response rate and duration of response demonstrated in phase 2 checkmate -275 trial.  Full Article

Bristol-Myers,Nordic Bioscience announce collaboration for fibrosis biomarker technology
Monday, 17 Apr 2017 06:59am EDT 

April 17 (Reuters) - Bristol-Myers Squibb Co ::Bristol-Myers Squibb and Nordic Bioscience announce collaboration for fibrosis biomarker technology.Collaboration to develop translational biomarkers for fibrotic diseases, including non-alcoholic steatohepatitis.  Full Article

More From Around the Web

BRIEF-Health Canada approves Bristol-Myers' opdivo(nivolumab)

* Health Canada approves opdivo (nivolumab) for the treatment of squamous cell carcinoma of the head and neck